Cost-effectiveness of HPV-vaccination in medium or low income countries with high cervical cancer incidence - A systematic review

Journal of Vaccines and Vaccination

Volumn 4, Issue 1, 2013, Pages 172-

  Natunen, Kari ^a   Lehtinen, T A ^a   Torvinen, S ^a   Lehtinen, M ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Anogenital cancers; Cervical cancer; HPV vaccination; hrHPV infections; Prophylactic vaccines

Indexed keywords

EID: 84879948559     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000172     Document Type: Article

References (106)

1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, et al. (2011) Worldwide burden of cervical cancer in 2008. Ann Oncol 22: 2675-2686.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-265.
4. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, et al. (2010) Human papilloma virus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048-1056.
5. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, et al. (2012) Global burden of human papillomavirus and related diseases. Vaccine 30: F12-F23.
6. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, et al. (2006) Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119: 2620-2623.
7. Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Macpherson LM (2006) Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)--recent trends and regional variation. Oral Oncol 42: 586-592.
8. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008) Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619.
9. Braakhuis BJ, Visser O, Leemans CR (2009) Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol 45: e85-e89.
10. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124: 1626-1636.
11. Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, et al. (2010) Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: The british columbia experience. Cancer 116: 2635-2644.
12. Blomberg M, Nielsen A, Munk C, Kjaer SK (2011) Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 129: 733-741.
13. Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11: 781-789.
14. Laara E, Day NE, Hakama M (1987) Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1: 1247-1249.
15. Peto J, Gilham C, Deacon J, Taylor C, Evans C, et al. (2004) Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 91: 942-953.
16. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S (2005) A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 89: S4-4S12.
17. Stanley M, Villa LL (2008) Monitoring HPV vaccination. Vaccine 26: A24-27.
18. Levi F, Lucchini F, Negri E, Franceschi S, la Vecchia C (2000) Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 36: 2266-2271.
19. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, et al. (2003) EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol 14: v61-118.
20. Gondos A, Chokunonga E, Brenner H, Parkin DM, Sankila R, et al. (2004) Cancer survival in a southern African urban population. Int J Cancer 112: 860-864.
21. Ries LAG, Eisner MP, Kosary CL (2004) SEER cancer statistics review, 1975-2001. Bethesda, Md, USA: National Cancer Institute.
22. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 89-99.
23. FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915-1927.
24. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
25. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 100-110.
26. Diaz M, Kim JJ, Albero G, de Sanjose S, Clifford G, et al. (2008) Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 99: 230-238.
27. Kim JJ, Goldie SJ (2009) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339: b3884.
28. Ezat WP, Aljunid S (2010) Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in malaysia. Asian Pac J Cancer Prev 11: 79-90.
29. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE (2008) Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 14: 244-251.
30. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER (2008) Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc 6: 4.
31. Sanders GD, Taira AV (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9: 37-48.
32. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13: 28-41.
33. Kim JJ, Goldie SJ (2008) Health and economic implications of HPV vaccination in the United States. N Engl J Med 359: 821-832.
34. Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N (2009) A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 9: 401.
35. Jit M, Choi YH, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769.
36. Kim JJ, Ortendahl J, Goldie SJ (2009) Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 151: 538-545.
37. Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B (2011) A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health 56: 153-162.
38. Kim JJ, Andres-Beck B, Goldie SJ (2007) The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97: 1322-1328.
39. Liu PH, Hu FC, Lee PI, Chow SN, Huang CW, et al. (2010) Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. BMC Health Serv Res 10: 11.
40. Lee VJ, Tay SK, Teoh YL, Tok MY (2011) Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 11: 203.
41. Taira AV, Neukermans CP, Sanders GD (2004) Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10: 1915-1923.
42. Dee A, Howell F (2010) A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 20: 213-219.
43. Kulasingam SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290: 781-789.
44. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, et al. (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96: 604-615.
45. de Kok IM, van Ballegooijen M, Habbema JD (2009) Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 101: 1083-1092.
46. Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, et al. (2010) Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 46: 2973-2985.
47. Obradovic M, Mrhar A, Kos M (2010) Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health 20: 415-421.
48. Olsen J, Jepsen MR (2010) Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 26: 183-191.
49. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, et al. (2007) Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25: 6257-6270.
50. Dasbach EJ, Largeron N, Elbasha EH (2008) Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res 8: 491-500.
51. Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S (2008) Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 24: 1473-1483.
52. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, et al. (2007) A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 4: 165-175.
53. Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH (2010) The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 13: 110-118.
54. Torvinen S, Nieminen P, Lehtinen M, Paavonen J, Demarteau N, et al. (2010) Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. J Med Econ 13: 284-294.
55. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, et al. (2011) Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 29: 2487-2494.
56. Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E (2009) Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 40: 503-513.
57. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U (2009) Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 27: 5133-5141.
58. Annemans L, Remy V, Oyee J, Largeron N (2009) Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 27: 231-245.
59. Dasbach EJ, Insinga RP, Elbasha EH (2008) The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115: 947-956.
60. Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, et al. (2008) The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev 9: 459-466.
61. Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, et al. (2009) The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 27: 6196-6202.
62. Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, et al. (2008) Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 26: 4015-4024.
63. Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, et al. (2009) Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 25: 161-170.
64. Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T (2009) Cost-effectiveness of human papilloma virus vaccination in Iceland. Acta Obstet Gynecol Scand 88: 1411-1416.
65. Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N (2009) Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 112: 370-376.
66. Vanagas G, Padaiga Z, Kurtinaitis J, Logminiene Z (2010) Cost-effectiveness of 12-and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. Scand J Public Health 38: 639-647.
67. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM (2007) Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26: 128-139.
68. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24: 10-19.
69. Brisson M, Van de Velde N, De Wals P, Boily MC (2007) The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25: 5399-5408.
70. Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, et al. (2008) Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26: 5654-5661.
71. Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J (2007) Cost-utility analysis of vaccination against HPV in Israel. Vaccine 25: 6677-6691.
72. Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N (2010) Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer 20: 385-392.
73. Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, et al. (2009) Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the netherlands. Vaccine 27: 4776-4783.
74. Coupe VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, et al. (2009) HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer 124: 970-978.
75. Colantonio L, Gomez JA, Demarteau N, Standaert B, Pichon-Riviere A, et al. (2009) Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 27: 5519-5529.
76. Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, et al. (2012) Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries. Value Health 15: S29-S34.
77. Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ (2012) Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG 119: 166-176.
78. Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, et al. (2011) Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics 29: 781-806.
79. Vanni T, Mendes Luz P, Foss A, Mesa-Frias M, Legood R (2012) Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. Vaccine 30: 4866-4871.
80. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, et al. (2012) Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 130: 2672-2684.
81. Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, et al. (2008) Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 26: M17-M29.
82. Vänskä P, Auranen K, Apter D, Kilpi T, Leino T, et al. Modelling high-risk human papillomavirus infection occurrence by type following mass vaccination.
83. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase no. 10. lyon, france.
84. http://data.worldbank.org/indicator/NY.GNP.PCAP.CD.
85. Engeland A, Haldorsen T, Tretli S, Hakulinen T, Horte LG, et al. (1995) Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis. A collaborative study of the five Nordic Cancer Registries. APMIS Suppl 49: 1-161.
86. United nations, department of economic and social affairs, population division (2009) world population prospects: The 2008 revision, highlights, working paper no. ESA/P/WP.210.
87. Laukkanen P, Koskela P, Pukkala E, Dillner J, Laara E, et al. (2003) Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 84: 2105-2109.
88. Laukkanen P (2012) Occurrence of high-risk human papillomaviruses and cervical cancer among fertile-aged women in finland. Acta Universitatis Ouluensis D 1187.
89. Arbyn M, Antoine J, Valerianova Z, Mägi M, Stengrevics A, et al. (2010) Trends in cervical cancer incidence and mortality in Bulgaria, Estonia, Latvia, Lithuania and Romania. Tumori 96: 517-523.
90. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World population prospects: The 2006 revision and world urbanization prospects: The 2007 revision.
91. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151: 1158-1171.
92. Canfell K, Barnabas R, Patnick J, Beral V (2004) The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 91: 530-536.
93. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, et al. (2007) Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166: 137-150.
94. Lehtinen M, French K, Dillner J, Paavonen J, Garnett G (2008) Sound implementation of human papillomavirus vaccination as a community-randomized trial. Therapy 5: 289-294.
95. French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, et al. (2007) Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age-and sex-specific pattern of vaccination in Finland. Br J Cancer 96: 514-518.
96. Ho GY, Kadish AS, Burk RD, Basu J, Palan PR, et al. (1998) HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 78: 281-285.
97. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24: S3/1-10.
98. Kapeu AS, Luostarinen T, Jellum E, Dillner J, Hakama M, et al. (2009) Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol 169: 480-488.
99. Dasbach EJ, Elbasha EH, Insinga RP (2006) Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28: 88-100.
100. Merikukka M, Kaasila M, Namujju PB, Palmroth J, Kirnbauer R, et al. (2011) Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 128: 1114-1119.
101. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, et al. (2010) Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 19: 1585-1594.
102. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, et al. (2012) Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 781-789.
103. Ben-Zion Y, Cohen Y, Shnerb NM (2010) Modeling epidemics dynamics on heterogenous networks. J Theor Biol 264: 197-204.
104. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, et al. (2007) Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96: 143-150.
105. Curtiss R 3rd (2011) The impact of vaccines and vaccinations: Challenges and opportunities for modelers. Math Biosci Eng 8: 77-93.
106. Merl D, Johnson LR, Gramacy RB, Mangel M (2009) A statistical framework for the adaptive management of epidemiological interventions. PLoS One 4: e5807.